Groups

Groups
E-mail Print PDF

2014

Daina A, Michielin O, Zoete V.
iLOGP: A Simple, Robust, and Efficient Description of n-Octanol/Water Partition Coefficient for Drug Design Using the GB/SA Approach.
J Chem Inf Model. 2014, 54(12):3284-301.


Chaskar P, Zoete V, Röhrig UF.
Toward On-The-Fly Quantum Mechanical/Molecular Mechanical (QM/MM) Docking: Development and Benchmark of a Scoring Function.
J Chem Inf Model. 2014, 54(11):3137-52.


Gfeller D, Grosdidier A, Wirth M, Daina A, Michielin O, Zoete V.
SwissTargetPrediction: a web server for target prediction of bioactive small molecules.
Nucleic Acids Res. 2014, 42(Web Server issue):W32-8


Röhrig UF, Majjigapu SR, Chambon M, Bron S, Pilotte L, Colau D, Van den Eynde BJ, Turcatti G, Vogel P, Zoete V, Michielin O.
Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
Eur J Med Chem. 2014, 12;84:284-301


Stockinger H, Altenhoff AM, Arnold K, Bairoch A, Bastian F, Bergmann S, Bougueleret L, Bucher P, Delorenzi M, Lane L, Le Mercier P, Lisacek F, Michielin O, Palagi PM, Rougemont J, Schwede T, von Mering C, van Nimwegen E, Walther D, Xenarios I, Zavolan M, Zdobnov EM, Zoete V, Appel RD.
Fifteen years SIB Swiss Institute of Bioinformatics: life science databases, tools and support.
Nucleic Acids Res. 2014, 42(Web Server issue):W436-41


Choudhary V, Darwiche R, Gfeller D, Zoete V, Michielin O, Schneiter R.
The caveolin-binding motif of the pathogen-related yeast protein Pry1, a member of the CAP protein superfamily, is required for in vivo export of cholesteryl acetate.
J Lipid Res. 2014, 55(5):883-94.


Crisante G, Battista L, Iwaszkiewicz J, Nesca V, Mérillat AM, Sergi C, Zoete V, Frateschi S, Hummler E.
The CAP1/Prss8 catalytic triad is not involved in PAR2 activation and protease nexin-1 (PN-1) inhibition.
FASEB J. 2014, 28(11):4792-805.


Barras D, Chevalier N, Zoete V, Dempsey R, Lapouge K, Olayioye MA, Michielin O, Widmann C.
A WXW Motif Is Required for the Anticancer Activity of the TAT-RasGAP317-326 Peptide.
J Biol Chem. 2014, 289(34):23701-11.


Peters S, Bouchaab H, Zimmerman S, Bucher M, Gaide O, Letovanec I, Homicsko K, Michielin O.
Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient.
Melanoma Res. 2014, 24(5):496-500.


Bordry N, Costa-Nunes CM, Cagnon L, Gannon PO, Abed-Maillard S, Baumgaertner P, Murray T, Letovanec I, Lazor R, Bouchaab H, Rufer N, Romano E, Michielin O, Speiser DE.
Pulmonary Sarcoid-like Granulomatosis after Multiple Vaccinations of a Long-term Surviving Patient with Metastatic Melanoma.
Cancer Immunol Res. 2014, 2(12):1148-53.


Romano E, Michielin O.
Successes and limitations of targeted cancer therapy in melanoma.
Prog Tumor Res. 2014;41:78-88.


Romano E, Michielin O, Voelter V, Laurent J, Bichat H, Stravodimou A, Romero P, Speiser DE, Triebel F, Leyvraz S, Harari A.
MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial.
J Transl Med. 2014, 12:97.


Meyer C, Cagnon L, Costa-Nunes CM, Baumgaertner P, Montandon N, Leyvraz L, Michielin O, Romano E, Speiser DE.
Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab.
Cancer Immunol Immunother. 2014, 63(3):247-57.


Dummer R, Goldinger SM, Turtschi CP, Eggmann NB, Michielin O, Mitchell L, Veronese L, Hilfiker PR, Felderer L, Rinderknecht JD.
Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.
Eur J Cancer. 2014, 50(3):611-21.


Kvistborg P, Philips D, Kelderman S, Hageman L, Ottensmeier C, Joseph-Pietras D, Welters MJ, van der Burg S, Kapiteijn E, Michielin O, Romano E, Linnemann C, Speiser D, Blank C, Haanen JB, Schumacher TN.
Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response.
Sci Transl Med. 2014, 6(254):254ra128.


 

google analytics